Cargando…
Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report
RATIONALE: The emergence of immune checkpoint inhibitors has brought new breakthroughs in the treatment of small cell lung cancer (SCLC). Programmed cell death-ligand 1 inhibitors combined with chemotherapy have been approved for the first-line treatment of extensive-stage small cell lung cancer (ES...
Autores principales: | Liu, Liang, Zhang, Xin, Zhou, Lihua, Yang, Tao, Qiao, Yun, Jiang, Xiaodong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416004/ https://www.ncbi.nlm.nih.gov/pubmed/34477165 http://dx.doi.org/10.1097/MD.0000000000027138 |
Ejemplares similares
-
Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022) -
Orbital adenoid cystic carcinoma treated by radiotherapy combined with anlotinib in a 13-year-old girl: A case report
por: Wu, Xue, et al.
Publicado: (2023) -
Esophago-tracheobronchial fistula following treatment of anlotinib in advanced squamous cell lung cancer: Two case reports
por: Zhang, Pin-Liang, et al.
Publicado: (2019) -
A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019) -
Mining prognostic factors of extensive-stage small-cell lung cancer patients using nomogram model
por: Gao, Hongxiang, et al.
Publicado: (2020)